NVMDF News and Press, Novamind Inc. From 09/09/21

TORONTO, ON / ACCESSWIRE / September 9, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that, effective today, its common shares have been approved for trading und...

TORONTO, ON / ACCESSWIRE / September 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the H.C. Wainwright 23 rd Annual Global Investment...

TORONTO, ON / ACCESSWIRE / August 11, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced that it has completed the sale of the Company's investment in the Synthesis Insti...

Samantha DeLenardo joins from CAMH, Canada's largest mental health teaching hospital and leader in mental health research TORONTO, ON / ACCESSWIRE / August 6, 2021 / Novamind Inc ., (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), leading mental health company specializ...

Company executes organic growth mandate, on track to open four new clinics by Q3 2021 TORONTO, ON / ACCESSWIRE / July 29, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased...

Aims to increase visibility and facilitate investment for United States investors TORONTO, ON / ACCESSWIRE / July 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased t...

Cedar Clinical Research to Host Phase IIb Trial for a Novel PTSD Treatment TORONTO, ON / ACCESSWIRE / July 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announ...

Aimed at an audience of psychedelic medicine researchers and clinicians TORONTO, ON / ACCESSWIRE / June 30, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced the la...

Led first-of-its-kind study of group psilocybin therapy for cancer patients with depression Co-Investigator on a study to evaluate ketamine as a treatment for opioid use disorder Will lead Novamind's clinical research arm focused on psychedelic medicine TORONTO, ON / ACCESSWI...

TORONTO, ON / ACCESSWIRE / June 17, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces that it has made a strategic investment of US$1,000,000 (the "Strategic Investment") in a s...